eyal

­

About eyal

This author has not yet filled in any details.
So far eyal has created 89 blog entries.

Principal Database Programmer

September 2nd, 2019|

 

JOB DESCRIPTION

Summary/Objective

This position is responsible for managing the delivery and execution of all technical aspects of Electronic Database Capture (EDC) study build including system components for lab management, randomization, drug supply, coding, and data transfer to the Pharmacovigilance database; validation and maintenance, including configuration of database build and parameters, performing update or migration activities […]

Clinical Supply Chain Management

September 2nd, 2019|

 

JOB DESCRIPTION

Summary/Objective

This position is responsible for managing clinical trial supply chain for Quark’s ongoing global late stage clinical trials. Responsibilities include management of clinical packaging/labeling, inventory control, distribution, shipping logistics and all other supply chain activities associated with delivering supplies to clinical sites. Position is responsible for ensuring availability of clinical trial material for […]

Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings

October 22nd, 2018|

FREMONT, Calif., Oct. 22, 2018 — Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced the acceptance of several abstracts on two major products, teprasiran (previously known as QPI-1002) and QPI-1007.

Teprasiran, an siRNA targeting the p53 gene, is under […]

Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

July 9th, 2018|

Quark reached agreement with FDA on the overall Phase 3 trial design with a new innovative primary endpoint
Fremont, CA –  July 9, 2018 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced the first patient dosed in the […]

Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

November 7th, 2017|

Fremont, CA – November 7, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the […]

Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

November 4th, 2017|

 Fremont, CA – November 4, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, presented today at the late breaking plenary session of the American Society of Nephrology (ASN) / Kidney Week positive results from a Phase 2 clinical study, […]

Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

November 1st, 2017|

Fremont, CA – November 1, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced that Phase 2 data on its lead program QPI-1002 will be presented as an oral abstract at the American Society of Nephrology (ASN) […]

Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference

October 9th, 2017|

FREMONT, Calif., Oct. 9, 2017 Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, is delivering an oral presentation at the 6th Annual RNAi China Conference in Jiangsu.

The presentation will summarize the preclinical efficacy data for inhaled small interfering RNA (siRNA) against an undisclosed […]

Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery

July 27th, 2017|

QPI 1002 Meets Primary & Multiple Secondary Endpoints
A statistically significant reduction in AKI incidence following cardiac surgery was demonstrated
First multicenter Phase 2 clinical study with an investigational drug for the prevention of AKI to meet primary endpoint
QPI-1002 appears to be well tolerated with no safety issues identified

Fremont, CA – July 27, 2017 – Today, Quark […]

Scientific Writer

March 8th, 2017|

 

Full-time or Contractor
Experienced in writing study reports for drug discovery programs including in vitro and in vivo Pharmacology studies
Reporting to CSO and working closely with Project Directors
M.Sc. in Biology or higher with at least 3 years industry experience
Experience in preparation of IND packages – advantage
Proficient in English (level of mother tongue)